Basic Research in Kidney Cancer

Overview

Journal Eur Urol

Specialty Urology

Date 2011 Jul 12

PMID 21741760

Citations 25

Authors

Egbert Oosterwijk

W Kimryn Rathmell

Kerstin Junker

A Rose Brannon

Frederic Pouliot

David S Finley

Peter F A Mulders

Ziya Kirkali

Hirotsugo Uemura

Arie Belldegrun

Affiliations

Soon will be listed here.

Abstract

Context: Advances in basic research will enhance prognosis, diagnosis, and treatment of renal cancer patients.

Objective: To discuss advances in our understanding of the molecular basis of renal cancer, targeted therapies, renal cancer and immunity, and genetic factors and renal cell carcinoma (RCC).

Evidence Acquisition: Data on recently published (2005-2011) basic science papers were reviewed.

Evidence Synthesis: Advances in basic research have shown that renal cancers can be subdivided based on specific genetic profiles. Now that this molecular basis has been established, it is becoming clear that additional events play a major role in the development of renal cancer. For example, aberrant chromatin remodelling appears to be a main driving force behind tumour progression in clear cell RCC. A large number of potential biomarkers have emerged using various high-throughput platforms, but adequate biomarkers for RCC are still lacking. To bring the potential biomarkers and biomarker profiles to the clinical arena is a major challenge for the field. The introduction of tyrosine kinase inhibitors (TKIs) for therapy has shifted the interest away from immunologic approaches. Nevertheless, a wealth of evidence supports immunotherapy for RCC. Interestingly, studies are now appearing that suggest a combination of TKI and immunotherapy may be beneficial. Thus far, little attention has been paid to patient-specific differences. With high-throughput methods becoming cheaper and with the advances in sequencing possibilities, this situation is expected to change rapidly.

Conclusions: Great strides have been made in the understanding of molecular mechanisms of RCC. This has led this field to the enviable position of having a range of molecularly targeted therapies. Large sequencing efforts are now revealing more and more genes responsible for tumour development and progression, offering new targets for therapy. It is foreseen that through integration of high-throughput platforms, personalised cancer treatment for RCC patients will become possible.

Citing Articles

LINC02532 Contributes to Radiosensitivity in Clear Cell Renal Cell Carcinoma through the miR-654-5p/YY1 Axis.

Zhou X, Zeng B, Li Y, Wang H, Zhang X Molecules. 2021; 26(22).

PMID: 34834139 PMC: 8625588. DOI: 10.3390/molecules26227040.

GRIM-19 deficiency promotes clear cell renal cell carcinoma progression and is associated with high TNM stage and Fuhrman grade.

Yan N, Feng X, Jiang S, Sun W, Sun M, Liu S Oncol Lett. 2020; 19(6):4115-4121.

PMID: 32382350 PMC: 7202299. DOI: 10.3892/ol.2020.11498.

Correlating Transcriptional Networks to Papillary Renal Cell Carcinoma Survival: A Large-Scale Coexpression Analysis and Clinical Validation.

Feng X, Zhang M, Meng J, Wang Y, Liu Y, Liang C Oncol Res. 2020; 28(3):285-297.

PMID: 31948514 PMC: 7851515. DOI: 10.3727/096504020X15791676105394.

miR-4521-FAM129A axial regulation on ccRCC progression through TIMP-1/MMP2/MMP9 and MDM2/p53/Bcl2/Bax pathways.

Feng X, Yan N, Sun W, Zheng S, Jiang S, Wang J Cell Death Discov. 2019; 5:89.

PMID: 31016032 PMC: 6465337. DOI: 10.1038/s41420-019-0167-5.

Loss of BAP1 Results in Growth Inhibition and Enhances Mesenchymal-Epithelial Transition in Kidney Tumor Cells.

Chen P, Wang H, Zhang W, Chen Y, Lv Y, Wu D Mol Cell Proteomics. 2019; 18(7):1320-1329.

PMID: 30992312 PMC: 6601205. DOI: 10.1074/mcp.RA119.001457.

References

Won Y, Song H, Kang T, Kim J, Han B, Lee S . Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics. 2003; 3(12):2310-6. DOI: 10.1002/pmic.200300590. View

DePrimo S, Bello C . Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol. 2007; 18 Suppl 10:x11-9. DOI: 10.1093/annonc/mdm409. View

Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M . Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol. 2009; 35(10):1119-23. DOI: 10.1016/j.ejso.2009.04.010. View

Laber D . Risk factors, classification, and staging of renal cell cancer. Med Oncol. 2007; 23(4):443-54. DOI: 10.1385/MO:23:4:443. View

Rini B . Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009; 27(19):3225-34. DOI: 10.1200/JCO.2008.19.9836. View

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

Skubitz K, Zimmermann W, Zimmerman W, Kammerer R, Pambuccian S, Skubitz A . Differential gene expression identifies subgroups of renal cell carcinoma. J Lab Clin Med. 2006; 147(5):250-67. DOI: 10.1016/j.lab.2006.04.001. View

Chow T, Youssef Y, Lianidou E, Romaschin A, Honey R, Stewart R . Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem. 2009; 43(1-2):150-8. DOI: 10.1016/j.clinbiochem.2009.07.020. View

Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr W . Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002; 1(3):237-46. DOI: 10.1016/s1535-6108(02)00043-0. View

10.

Linehan W, Bratslavsky G, Pinto P, Schmidt L, Neckers L, Bottaro D . Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010; 61:329-43. PMC: 2921612. DOI: 10.1146/annurev.med.042808.171650. View

11.

Seliger B, Massa C, Rini B, Ko J, Finke J . Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol Med. 2010; 16(4):184-92. DOI: 10.1016/j.molmed.2010.02.001. View

12.

Perez-Gracia J, Prior C, Guillen-Grima F, Segura V, Gonzalez A, Panizo A . Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer. 2009; 101(11):1876-83. PMC: 2788252. DOI: 10.1038/sj.bjc.6605409. View

13.

Thoenes W, Storkel S, Rumpelt H . Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986; 181(2):125-43. DOI: 10.1016/S0344-0338(86)80001-2. View

14.

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

15.

Huang W, Sheehy T, Moore L, Hsing A, Purdue M . Simultaneous recovery of DNA and RNA from formalin-fixed paraffin-embedded tissue and application in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010; 19(4):973-7. PMC: 2864144. DOI: 10.1158/1055-9965.EPI-10-0091. View

16.

Tanimoto K, Makino Y, Pereira T, Poellinger L . Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000; 19(16):4298-309. PMC: 302039. DOI: 10.1093/emboj/19.16.4298. View

17.

Jung M, Mollenkopf H, Grimm C, Wagner I, Albrecht M, Waller T . MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 2009; 13(9B):3918-28. PMC: 4516539. DOI: 10.1111/j.1582-4934.2009.00705.x. View

18.

Ng C, Novick A, Tannenbaum C, Bukowski R, Finke J . Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. Urology. 2002; 59(1):9-14. DOI: 10.1016/s0090-4295(01)01503-5. View

19.

Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A . Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest. 2004; 84(7):845-56. DOI: 10.1038/labinvest.3700097. View

20.

Nogueira M, Kim H . Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol. 2008; 26(2):113-24. DOI: 10.1016/j.urolonc.2007.03.028. View